Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

GVHD RIG I STING Research

News and Trends 25 Apr 2017

New Research could Save Patients from Graft-Versus-Host Disease

A new study published in the journal Science Translational Medicine identifies a new treatment strategy to prevent GVHD after stem cell transplantation. Allogeneic stem cell transplantation remains one of the top treatments for blood cancers and inherited blood disorders, but the treatment is associated with a major risk of so-called graft-versus-host disease (GVHD). A new paper […]

April 25, 2017 - 3 minutesmins - By Melanie De Almeida

Genfit NASH enrollment delay

News and Trends 24 Apr 2017

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […]

April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview Mark Post cultured meat Mosa Meat

Interview 24 Apr 2017

‘Meat’ the Founder behind the Lab-Grown Burger Investors are Queuing for

Mark Post is a researcher at the University of Maastricht and co-founder and CSO of Mosa Meat, the Dutch company that will bring the first lab-grown beef burger to the market. I asked him about his motivations and plans to make cultured meat a reality in the coming decade. Cultured meat is an animal-free, lab-grown […]

April 24, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

Anna Dumitriu CRISPR Bioart Antibiotic

News and Trends 22 Apr 2017

Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance

Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […]

April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

top 5 expensive drugs

News and Trends 21 Apr 2017

The World’s Most Expensive Drugs have European Owners

A new report has listed the world’s most expensive drugs. Not surprisingly, those targeting rare diseases bear the heaviest price tags – let’s have a look. While biotechs like Généthon and EspeRare are rethinking the high-risk high-profit model and looking to provide treatments at an affordable price, most rare disease meds on the market are among the most […]

April 21, 2017 - 4 minutesmins - By Melanie De Almeida

fungi secondary metabolites genome sequencing

News and Trends 21 Apr 2017

Fungi Genomes could be a Gold Mine of New Antibiotics

Good old Penicillium still has a lot more tricks upon its sleeve: Swedish researchers see its potential as a gold mine for new antibiotics. The genomic analysis of Penicillium species represents a potential gold mine for new bioactive compounds, or improved versions of those we already use. Published recently in Nature Microbiology, the work was carried at Chalmers University […]

April 21, 2017 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

Prokarium Oral Vaccines

Startup Scout 21 Apr 2017

No more Needles – This UK Biotech is Developing Innovative Oral Vaccines

The small village of Keele is probably best known for its university, but it also hosts the Keele Science Park, where the biotech company Prokarium is developing new oral vaccine solutions based on synthetic biology. Mission: Prokarium has the vision that all protein vaccines can be delivered orally. Founded in 2012, the company has developed an oral […]

April 21, 2017 - 2 minutesmins - By Melanie De Almeida

shutterstock 623999072

News and Trends 20 Apr 2017

Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn

The excitement about the therapy was undercut when it became clear Glybera would be a commercial failure. In October, it will officially be dead. uniQure has announced that it will not go for the renewal of its marketing authorization for Glybera in Europe, which is set to expire in October this year. Since Glybera missed approval in the […]

April 20, 2017 - 3 minutesmins - By Evelyn Warner

Stefan Weber CEO Newron Pharmaceuticals Labiotech Meetup Munich

Interview 20 Apr 2017

Newron’s Journey to Launch the First Parkinson’s Drug in 11 Years

Philip talked to Stefan Weber, CEO of Newron Pharmaceuticals, in our first meetup in Munich last week. His company has launched a new drug that could offer many more benefits than current medications to patients with Parkinson’s. Stefan discussed how failure can be an important part of success and what being European means in biotech. […]

April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Targovax rectal cancer TG02 Phase I 1

News and Trends 20 Apr 2017

Norway Brings Another Cancer Vaccine to the Clinic

Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell division and are a key driver of cancer progression and treatment resistance. The Norwegian biotech Targovax is developing peptide-based anti-cancer vaccines targeting these mutations found […]

April 20, 2017 - 3 minutesmins - By Melanie De Almeida

Advent France Biotechnology Seed Fund

News and Trends 20 Apr 2017

New French Biotech Seed Fund Raises €65M in its First Closing

Advent France Biotechnology has launched its first seed fund for Life Sciences with the support of Bpifrance and Advent Life Sciences. Advent France Biotechnology, founded in 2015, has exceeded its initial fundraising target at the first closing. Its Seed-Fund I now counts with €64.75M that will be invested predominantly in France. The funds will back entrepreneurs […]

April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Immuno oncology Europe company poll

Interview 20 Apr 2017

Which EU Immuno-Oncology Company are you Cheering for?

Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one do you think is doing it best? The field of immuno-oncology is overcrowded, and there’s plenty of companies pushing to make their cutting-edge technology a […]

April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

ADVERTISEMENT